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Egg sharing is a procedure in which a woman who is herself undergoing assisted-conception
treatment receives subsidized treatment in exchange for sharing her eggs with another woman.
It has become increasingly prevalent in the UK and is the major source of donor eggs in the UK;
however, its practice is controversial. Available evidence concerning the outcomes of egg
sharing is limited. To date, while this has failed to provide strong empirical support for concerns
that have been raised regarding egg sharing, continuing significant gaps in information
regarding clinical and psycho–social outcomes remain, which mean that an informed judgment
on empirical grounds cannot yet be made. Ongoing key ethical controversies focus on the
impact of egg sharing on the commodification of human gametes and whether women can
genuinely consent to donating their eggs under an egg-sharing scheme.
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Technological developments in reproductive
healthcare have increased the options available to
people seeking to overcome fertility impairments
– including treatments using gametes provided
by a third party. In practice, although some juris-
dictions prohibit donor remuneration, payment
to ‘donors’ is common. Such payment necessarily
confounds the accepted definition of ‘donor’. In
accordance with common usage in the assisted
reproductive technologies (ART) literature, we
have employed the terms ‘donor’ and ‘donation’
in this paper, but the reader should be aware of
this caveat. While insemination of donor sperm
has been used as a medicalized procedure for well
over a century [1], IVF using donor eggs is a
much more recent phenomenon; the first birth
from such a procedure was reported in Australia
in 1984, using an egg provided by an IVF
patient [2]. It is quite possible, although the
authors do not provide details of the arrange-
ments under which the donation took place,
therefore, that the very first reported birth
through egg donation was in fact the result of
egg sharing. Use of donor eggs is clinically indi-
cated for women seeking to conceive who have
experienced primary or secondary ovarian fail-
ure, who have functioning ovaries but for whom
standard ovarian stimulation drug regimes have
failed or where there is a risk of transmitting a
serious genetic disorder to a child [3].
Use of donor eggs has become especially preva-
lent in ART procedures for older women (i.e.,
women aged over 40 years), for two inter-related
reasons; first, because of the significant decline in
female fertility once women reach their mid-
30s [4] and the more rapid decline after the age of
40 years [101], and second, because the likelihood
of successful embryo implantation is related to the
age of the woman providing the egg rather than to
the age of the woman in whom the embryo is
implanted [5]. US data show that while fewer than
3% of all women undergoing an ART procedure
during 2005 used donor eggs, 22% of women
aged 41–42 years, 55% of women aged over
42 years did so, while 90% of ART cycles under-
taken by women aged over 47 years utilized donor
eggs [5]. A total of 52.3% of all embryo transfers
undertaken in 2005 in the USA using fresh donor
eggs resulted in a live birth and 30.9% of transfers
using frozen–thawed donor eggs resulted in a live
birth. By comparison, 34.3% of transfers using
fresh nondonor eggs and 28.0% of transfers using
frozen–thawed nondonor eggs resulted in a live
birth. These data illustrate the higher success rates
of procedures using fresh contrasted with fro-
zen–thawed embryos and of procedures using
eggs provided by young and healthy donors.
European data for ART outcomes in 2003
from 28 countries show a similar trend [6]. While
outcomes in the most ‘successful’ European
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countries appear comparable with those of the USA, lower
rates are reported for European countries overall, as there are
considerable variations between countries. These differences
may be attributable to a range of factors, including superior
clinical skills and technological facilities, and transfer of a
higher number of embryos per cycle. Higher US rates of suc-
cess for procedures using donor eggs may also be affected by
greater access to paid egg providers (this is prohibited in a
number of European countries). Indeed, egg donation in the
USA is a highly commercialized industry, utilizing eggs pro-
vided by young women charging variable fees dependent on
their educational, ethnic, health and physical profile [7].
Allowance also needs to be made for the fact that the Euro-
pean data relate to procedures undertaken 2 years earlier than
in the USA, and – assuming improvement in outcomes over
time – that fewer differences might be apparent in a ‘like-for-
like’ comparison. However, true intercountry comparison is
compromised by the small number of procedures reported in
some countries. A total of 37.9% of embryo transfers using
donor eggs (outcomes for fresh and frozen–thawed donor
eggs are not reported separately) resulted in a pregnancy,
ranging from 14.3 (France) to 55.2% (Spain). An overall
delivery rate for all countries included in the survey is not
available due to incomplete data or an absence of pregnancy
follow-up in some countries; however, available data show
delivery rates ranging from 6.5 (Belgium) to 50.0% (Iceland
and Ireland). Comparative data for transfers using fresh non-
donor eggs show a mean clinical pregnancy rate per embryo
transfer of 29.6%, ranging from 20.8 (Austria) to 44.4% (Ice-
land). Overall delivery rates per embryo transfer are also
unavailable; however, data for individual countries range
from 7.4 (Belgium) to 31.6% (Iceland). A total of 18.6% of
embryo transfers using frozen nondonor eggs resulted in a
pregnancy, with intercountry ranges of 0 (Lithuania, where
only seven transfers were reported during 2003) to 33.0%
(Greece). Delivery rates per transfer using frozen nondonor
eggs ranged from 0 (Lithuania) to 23.5% (Iceland).
However, use of donor eggs in ART is not universally
accepted. The most comprehensive international review to
date, providing an overview of ART in 57 countries, reported
that use of donor eggs is expressly prohibited in China,
Croatia, Egypt, Germany, Italy, Japan, Morocco, Norway, the
Philippines, Switzerland, Tunisia and Turkey, and donor eggs
are not used in Austria, Jordan or Malaysia [8].
Where use of donor eggs is permitted, demand typically
exceeds supply, irrespective of the conditions in which egg-
donor procedures are undertaken. This disparity may be more
acute where overt payment to donors is prohibited or where
they may be required to disclose their identity to any offspring
– although it is also possible that the latter factor might be bal-
anced, at least in part, by a reduction in demand, since fewer
potential recipients might wish to use eggs provided by an iden-
tifiable than an anonymous donor [9]. A variety of sources of
donor eggs has been reported, which include the following:
• Women undergoing sterilization; 
• Specifically recruited donors (who, depending on national
requirements and/or practices may or may not receive finan-
cial remuneration; may or may not be already known to the
recipient – especially as a friend or family member – and,
depending on jurisdictional requirements, may or may not be
required to agree that any offspring wishing to know their
identity may be able to do so – or in the absence of mandated
identity disclosure may be offered the option of agreeing to
disclose their identity to any offspring);
• Women who are themselves undergoing fertility treatment
(with similar arrangements to those outlined previously
regarding disclosure of their identity to any offspring).
Egg sharing
The latter form of egg donation is typically described as egg
sharing and, in the UK, has specifically developed as a form of
discounted IVF treatment, where the donor is able, by sharing
her eggs with up to two recipients, to offset the costs of her
own treatment, which is subsidized by the recipient(s) of her
eggs. Egg sharing is also a term used when eggs provided by a
single donor are shared between multiple recipients [6,10]. This
variant of egg sharing is not discussed in this paper. Egg shar-
ing should also be distinguished from ‘egg giving’, a procedure
in which the donor undergoes a stimulation and retrieval cycle
from which all available eggs are donated to one or more
recipients, followed by a second, subsidized cycle in which the
donor retains all available eggs for her own treatment. Com-
pared with egg sharing, egg giving is claimed to offer
improved chances of conceiving to both the egg provider and
recipient and, in addition, increase the opportunities for the
recipient of conceiving two or more children fully genetically
related to each other. However, egg giving was prohibited by
the UK’s regulatory body, the Human Fertilisation and
Embryology Authority (HFEA) on the grounds that the egg
‘giver’ would be required to undergo two stimulation and
retrieval cycles in order to obtain her own treatment, and
would derive no benefit from the first cycle other than the
right to have her own treatment cycle at reduced cost [11].
Currently, it is claimed that an egg-share donor would pay
upwards of £600 towards the cost of a single IVF cycle, while
the recipient would pay up to £6000 [102].
In jurisdictions that permit egg donation but prohibit donor
remuneration, egg sharing is also generally prohibited or not
practiced – and may be practiced infrequently in jurisdictions
where payment to gamete providers is permitted. Egg sharing
has been reported in Australia [12], Belgium [13–15], Canada [16],
Greece [12], Spain [12], the UK [12,17–26,103,104] and the
USA [27–37], and was practiced in Italy until legislation passed
in 2004 that prohibited all forms of donor and third-party-
assisted-conception procedures [38–39]. It is the sole legally per-
missible form of egg donation in Denmark [3,105] and Israel [40].
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According to anecdotal information, egg sharing is also avail-
able in other countries (e.g., India and Poland), thus its true
prevalence globally remains uncertain.
In relation to the countries in which egg sharing has been
documented, consideration of relevant ethical issues needs to
take account of variant arrangements for funding ART services
– and therefore, the extent to which access to treatment is
dependent on an individual’s ability to pay. Limited state fund-
ing of ART in the UK, for example, contrasted with generous
public funding in Belgium, Denmark and Israel, means that the
contexts in which egg sharing is practiced are quite different,
even among this limited range of countries.
Egg sharing in the UK
Assisted reproductive technologies services in the UK are funded
variably by the NHS. Access to NHS-funded ART services is
largely determined on the basis of residence, in effect resulting
in a so-called ‘postcode lottery’. Sharing their eggs might there-
fore be seen as being of potential interest to women who are
unable to access NHS treatment at all, women who have used
up their entitlement to NHS-funded treatment and women eli-
gible for NHS-funded treatment who could have one or more
egg-sharing cycles while on the waiting list for NHS treatment.
Egg sharing in the UK was developed and promoted in the early
1990s by Ahuja and Simons with three specific objectives: as a
means of addressing the supply–demand disparity, by accessing
an additional source of donor eggs; to provide treatment oppor-
tunities for women who otherwise might be unable to afford
treatment at all or who might have to delay treatment while sav-
ing up to pay for it; and to reduce reliance on – or avoid com-
pletely – the recruitment of nonpatient donors who would be
exposed to the risks associated with ovarian stimulation and egg
retrieval [17,18,20,25]. The first birth resulting from egg sharing in
the UK was reported in 1992 [25]. Legally, egg sharing was made
possible by the fact that ‘payment in kind’ to donors has never
been prohibited in the UK, although when the HFEA began
operations in 1991 it pegged overt donor remuneration for all
gamete donors at £15. This was the average payment made to
sperm donors by UK clinics at that time. Since egg donation
was little practiced in the UK then, it did not impact formal
decisions regarding donor remuneration.
During the 1990s, egg sharing was available at relatively few
UK clinics [41] and, in 1998, survived an attempt by the HFEA
to have it outlawed as part of a policy to completely terminate
financial remuneration to gamete providers. The HFEA’s deci-
sion to abandon these plans resulted from overwhelming opposi-
tion from clinics and insufficient support from a wider public
consultation. However, in acknowledging egg sharing as a for-
mally licensed procedure, the HFEA stated that “allowing egg-
sharing to continue did not mean that the HFEA had given the
practice its ethical approval” [106]. This seems strikingly bizarre,
since it meant that the HFEA was countenancing the regulation
of a procedure whose ethical credentials it doubted. Nevertheless,
as a consequence of what many clinics perceived as the HFEA’s
‘green light’ for egg sharing, the number providing egg sharing
grew after 1998 and by 2007 had risen to 47 – well over half of
all licensed clinics [42]. By 2005, egg sharing was identified as the
source of approximately two-thirds of all donor eggs [43] and it is
estimated that at least 2000 children have been born to both
egg-share donors and recipients [25].
In 2005, anticipating implementation of the EU Tissue Direc-
tive, limiting compensation to donors to “making good the
expenses and inconveniences related to the donation” [44], the
HFEA developed a framework for gamete donor remuneration
ostensibly driven by a policy of ‘cost neutrality’ in which donors
should neither profit nor be financially disadvantaged as a con-
sequence of donating, which would not provide compensation
for inconvenience. The opportunity provided by this review was
taken by the HFEA to revisit egg sharing, which it has contin-
ued to sanction – justifying the element of subsidy as compensa-
tion for the element of the procedure in which the egg provider
acts as a donor [11]. This is discussed in more detail later.
Concerns regarding egg sharing
Criticisms of egg sharing may be distinguished as either empirical
or ethical concerns. With regards to empirical concerns, a recipi-
ent may compromise her own chances of successful treatment by
using eggs provided by a woman who, herself, has fertility diffi-
culties [23,45]. A donor may compromise her chances of successful
treatment by not retaining all her available eggs (if necessary
and/or possible, cryopreserving some eggs for use in a future
cycle) and may expose herself to increased risk if she has to
undergo additional stimulation, egg retrieval and transfer
cycles [23,45,46]. She may also be subjected to stronger ovarian
stimulation (and consequent risk of ovarian hyperstimulation) in
order to maximize the number of available eggs and ensure a suffi-
cient number of eggs to share with at least one recipient [11]. The
distribution of available eggs may favor the interests of the (pay-
ing) recipient at the expense of those of the donor [23]. In addition
to physical risks associated with the procedure, a donor whose
own treatment is eventually unsuccessful may experience emo-
tional difficulties if she knows or believes that the recipient of her
egg(s) may have succeeded in having a child [45,46,103]. The 2005
legislative change in the UK requiring all gamete providers to
agree to the disclosure of their identity to any offspring reaching
the age of 18, has been cited as potentially aggravating this prob-
lem: “… you could potentially have a woman who is infertile who
is unsuccessful but who donates eggs to someone who is success-
ful and a child then potentially might want to visit that ‘poor
infertile woman’ some 20 years down the track” [107] – our
emphasis. Templeton [102] and Winston [108] make a similar point.
One self-evident shortcoming of empirical concerns relates to
the lack of evidence to support (or indeed to confound) them.
There are few clinical studies of egg sharing and only a small
number of these have compared outcome data for donors with a
matched group of women undergoing regular IVF cycles or
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outcome data for egg-share recipients with a matched group of
women undergoing treatment with eggs from nonpatient
donors. Several reports provide no information regarding out-
comes for donors at all [29,32–34,37]. Others, while providing out-
come data for both donors and recipients, are restricted to preg-
nancy – or to pregnancy and implantation outcomes only – and
provide no information regarding live births [19,28,30,31,35,36,38].
Only five studies provide data regarding live-birth outcomes for
donors [14,17,25,26,34]. A single published paper has compared
pregnancy and live-birth rates for donors, egg-share recipients
and women undergoing nonegg-sharing standard IVF cycles [26].
Some provisional findings may be discerned from these studies.
Recipients using eggs provided by an egg-share donor are not
exposed to reduced pregnancy or implantation rates [26,32,33,37].
Compared with similar aged women using their own eggs, older
women using eggs provided by a third party achieve higher
pregnancy and implantation rates [13,47]. This is probably the
result of using eggs provided by younger women. Pregnancy
and implantation rates are similar for donors and for women
using their own gametes in standard IVF [26,31]. Donors do not
appear to be exposed to a higher potential risk of ovarian hyper-
stimulation syndrome [26]; nor does the allocation of available
eggs discriminate against donors [21,26]. Current regulations in
the UK are designed to ensure an equal distribution of available
eggs (subject to a minimum number of eggs being available in
any one cycle) between the donor and a single recipient,
although eggs may be shared with a maximum of two recipients
in any single cycle [48]. Although studies have shown higher
pregnancy and live-birth rates for recipients than for donors,
the reported results do not always achieve statistical
significance [17,26–28,30,31,34,36,38,49]; however, the evidence is
contradictory. Research conducted by Kolibianakis et al. found
no significant difference in delivery rates between donors and
recipients [14], while Thum et al. found that both pregnancy and
live-birth rates were similar for donors, egg-share recipients and
women using their own gametes undergoing standard IVF [26].
Flamigni et al. reported a slightly lower pregnancy rate for recip-
ients than donors [38]; however, when donors and patients were
matched for age, the donors had slightly reduced pregnancy and
implantation rates. In a UK newspaper article focusing on the
potential problems of the egg-share donor who remains child-
less, Templeton reported selected HFEA data for egg-share
cycles undertaken between 1999 and 2005, noting that 770 of
4140 cycles resulted in the delivery of a baby to recipients
only [102]. However, the same HFEA data indicate that, based
on ‘matched’ cycles (i.e., where eggs from a donor cycle can be
tracked through to a recipient cycle), 1141 of 4140 donor cycles
during this period resulted in a live birth (27.56%) and 1093 of
4526 recipient cycles resulted in a live birth (24.15%) [BLYTH,
PERS. COMM.]. More recipient cycles than donor cycles are reported
because eggs may be donated to up to two recipients.
To date, empirical studies of views and experiences of partici-
pants in egg-sharing programs are confined to surveys under-
taken by a single London clinic [17,18] and two small-scale
exploratory studies reporting on in-depth interviews with
donors [22,24], the latter including the donor’s partner. These
have investigated donors’ motivations and decision-making
processes, their perceptions of egg sharing, how they would
anticipate dealing with eventual treatment failure and how
information regarding egg sharing may be managed within
their families. These studies have not produced any evidence
that donors or recipients in general experience any particular
emotional or psychological difficulties or that donors who
remain childless either experience such difficulties or regret
their decision; however, the limitations of these studies need to
be acknowledged. They are based on relatively small numbers
of respondents or participants and are likely to under-represent
those with negative views and experiences of egg sharing. They
have sought participants’ views at a single moment in time,
which may change in the future. Therefore, it may well be the
case that donors such as the woman cited by Blyth [22]: “I
would do it again even though my own treatment failed. I
would still do it again. I would still like to think that I was giv-
ing somebody else a chance” may have quite different feelings
and views if the ‘possibility’ of treatment failure becomes a ‘cer-
tainty’. The limited scope of these studies also means that there
is no empirical evidence concerning the longer term
psycho–social outcomes for either donors or recipients and
other members of their families, including any children con-
ceived as a result of egg sharing. The three principal ethical
arguments raised against egg sharing relate to:
• Donors subsequently regretting their decision;
• The risk of invalidated consent;
• The commodification of reproductive tissue.
The donor who subsequently regrets her decision
This argument is frequently set alongside a scenario in which
the donor’s own treatment is unsuccessful, while the recipi-
ent(s) of her egg(s) is/are successful in conceiving a child and is
compounded by the hypothetical instance of the ‘childless’
donor being contacted some 18 or so years later by an adult
offspring [9,107,108]. Judged purely in terms of a donor’s poten-
tial or actual regret or change of mind, we would argue that
this does not provide a sufficient reason to invalidate the origi-
nal decision. On a daily basis we are all faced with having to
make decisions. Not only will we be very fortunate indeed if
we never come to regret a past decision, but a regretted deci-
sion does not provide a legitimate basis for not making the
decision in the first place, nor for denying an individual the
opportunity to make it. Clearly, there are issues related to ser-
vice providers making all relevant information available to the
individual (which is required by the HFEA in its Code of Prac-
tice and where, in our view, it would be unethical to withhold
relevant information, including information regarding the very
tangible limits to current knowledge concerning the clinical
and psycho–social outcomes of egg sharing).
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As we have indicated, our views take account only of the
perspective of the donor and, as we have noted previously, we
know nothing regarding the perspectives and experiences of
individuals who have been conceived as a result of egg sharing.
This omission must be urgently addressed and, if it becomes
apparent that those conceived as a result of egg sharing articu-
late concerns regarding the practice, this would provide suffi-
cient grounds for a systematic review of its appropriateness –
taking into account the views of all interested parties.
Compromised consent
The possibility that egg sharing may represent the only alter-
native to having no treatment is subject to widely divergent
views. On the one hand, it is lauded as extending women’s
options [17,18]; on the other, it is portrayed as no real choice at
all, where a woman’s desire to have a child may result in her
being manipulated into endorsing any procedure that may
hold out the possibility of assisting her to do so [50]. Faced
with an option such as egg sharing, a woman may be encour-
aged to disregard the risks because of the potential prize of a
much-wanted baby and may therefore not actually provide
valid consent [50,103]: “For those who desperately want chil-
dren but cannot afford to pay for treatment, egg sharing repre-
sents their only option. Where there is such a large induce-
ment to donate eggs, questions must be raised about the
validity of the consent and whether it meets the requirement
that, in order to be valid, consent must be given voluntarily
and free from pressure” [103].
Similar criticisms have been made by Lieberman [104] and
Johnson [23]. The principle of informed consent is set out in
Article 1 of the Nuremburg Code: “The voluntary consent of
the human subject is absolutely essential. This means that the
person involved should have legal capacity to give consent;
should be situated as to be able to exercise free power of
choice, without the intervention of any element of force … or
other ulterior form of constraint or coercion; and should have
sufficient knowledge and comprehension of the elements of
the subject matter involved as to enable him to make an
understanding and enlightened decision …” [51].
Our analysis accepts first that the monetary value of the
subsidized treatment cycle is indubitably an inducement to a
potential egg sharer, as indeed, is any ‘feel-good’ factor that
may derive from ostensibly altruistic donation. There is a
general acceptance, even where the principle of material
reward to gamete donors is conceded, that “Both monetary
compensation and [egg] sharing create the possibility of
undue inducement and exploitation in the [egg] donation
process” [46]. Recognizing such risks, the Ethics Committee of
the American Society for Reproductive Medicine has put a
price on exploitation, asserting that “Total payments to [egg]
donors in excess of US$5000 require justification and sums
above US$10,000 are not appropriate” [46]. The key ethical
question is whether it is an excessive inducement to the
extent that the donor’s consent is invalidated. Second, that
decisions we all make are necessarily circumscribed to some
extent [52]. Here, the Nuremberg Code’s qualification that any
form of constraint or coercion must not be ‘ulterior’, perhaps
provides a basis for Lockwood’s ostensibly pragmatic descrip-
tion of egg sharing as “… a form of coercion; it is just ‘a more
acceptable form of coercion’ than the usual ones” (our
emphasis) [109].
Johnson, a noted critic of egg sharing, also concedes that the
complete absence of constraint on decision making may be
unrealistic when he states that “[Effective consent] should be
informed and given ‘as free as possible’ from pressure or coer-
cion” (our emphasis) [23]. A Belgian study noted that the num-
ber of women agreeing to share their eggs dropped by approxi-
mately 70% following the decision by the Belgian government
to provide free IVF from 1 July 2003, illustrating the impact
of financial considerations on egg-share donors’ motivation
and what the authors concluded to be “A degree of
coercion” [15]. Although they did not consider the impact of
access to expeditious treatment as a motivating factor for erst-
while donors, the authors nevertheless acknowledged the
multidimensional nature of motivation and the potential con-
tribution of altruism in egg sharing. Data from the study indi-
cated that financial factors provided a significant motivation
for many donors, but did not identify those who might be
willing to assist other women in a similar position, so long as
the arrangement provided some return for themselves. Thus,
self-help and a desire to help others may coexist – the offer of
free treatment being ‘the extra push that makes them donate.’
In general, the ability to give consent is complex; it has also
been mooted that “The complexity of informed consent
hangs on the fact that it can go wrong either in the informing
or in the consenting” [53]. The HFEA, despite its reservations
regarding the ethics of egg sharing to which we have earlier
referred, requires consent to be obtained before any licensed
procedure, including egg sharing, can be undertaken [54], so it
clearly does not consider obtaining consent from an egg-share
donor to be unachievable. What has clearly been absent from
this debate so far has been the views of egg-share donors
themselves and whether, at the time of undergoing the proce-
dure and on subsequent reflection, they consider that their
consent was properly obtained. The current limited evidence
from empirical studies that have asked participants in egg-
sharing programs indicates that donors themselves feel
equipped to make valid choices regarding participating in egg
sharing [17–19,24] – and some women who contemplated egg
sharing decide not to proceed after they have had the oppor-
tunity to consider its implications for them [22]. Conse-
quently, egg sharing is not simply perceived as an offer that is
‘too good’ for potential donors to refuse. However, ascertain-
ing views regarding informed consent was not a primary
objective of any of these studies, thus adequate analysis of
egg-share donors’ views and experiences of informed consent
remains to be undertaken.
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Egg sharing & egg trading
Where donor remuneration is formally sanctioned, as in the
USA, official rhetoric emphasizes that donor compensation
should reflect the “Time, inconvenience, and discomfort associ-
ated with screening, ovarian stimulation, [and egg]
retrieval” [46]. Similarly, the International Federation of Fertility
Societies proscribes payment for providing the eggs, but “This
does not exclude reimbursement for expenses, time and risk
which are associated with the donation” [55].
In striving to maintain its position of permitting egg sharing
within the overall policy of nonremunerated gamete donation
(which does not permit compensation for time, inconvenience,
discomfort or risk), the HFEA has tried a different tack, by
contrasting the provision of donor-assisted conception services
(i.e., largely commercial services) with other forms of medical
treatment using donated tissue (provided largely within the
NHS): “Thus a reduction in the charges made to an egg pro-
vider need not be seen as a payment for her eggs but a recogni-
tion that a part of her treatment involves an egg donation and,
as such, should not be chargeable to her” [11].
Given that the commercial value of a discounted IVF
treatment cycle in egg sharing runs to several thousand
pounds [102,110] and is considerably in excess of the current limits
imposed on donor remuneration by the HFEA, critics have
complained that egg sharing is merely an attempt to bypass pro-
hibitions on donor payment [23,104]; Lieberman in particular
asserting that: “The eggs are not being donated; they are being
traded for treatment” [104]. Johnson has identified further prob-
lems arising from what he sees as the commodification of gamete
procurement through egg sharing: undermining not only the
integrity of the child conceived through egg sharing both as
(s)he and others perceive him/her, but also the rights of all of us
“not to be regarded as commodities or be instrumentalized” [23].
The Ethics Committee of American Society for Reproductive
Medicine proposes what it considers a more upfront approach
to the perceived contradictions of egg sharing, eschewing any
pretence that subsidized IVF cycles represent legitimate com-
pensation for donation only [46]. It advocates acknowledging
overtly the commercial nature of egg sharing and the need to
focus debate on whether resultant ethical concerns are out-
weighed by the benefits of increased access to ART services.
There is clearly a wide spectrum of views regarding the anal-
ogy between egg sharing and overt commercialization of gamete
procurement. Participants in egg sharing arrangements them-
selves have distinguished between egg sharing and the sale of
gametes, emphasizing the importance of a desire to help others
in a similar position as well as themselves [15,17,18,22,24,56].
Expert commentary
In the UK, egg sharing has provided a significant source of
donor eggs. It has resulted in the birth of more than 2000 chil-
dren and has therefore enabled many women, who may not
otherwise have done so, to fulfill their quest to conceive a child.
The current, limited research evidence regarding clinical out-
comes has not provided any significant indication that the prac-
tice carries with it particular risks for either donors or recipi-
ents. We recognize that lack of evidence of risk is not the same
as evidence of lack of risk, and outcomes of the procedure for
both donors and recipients should continue to be monitored
and reported. Clinical researchers should facilitate methodolo-
gies and approaches that allow for more effective interstudy
comparisons than has been achieved in the past, in particular,
providing comparative pregnancy and live-birth data for both
donors and recipients.
As we have indicated, significant aspects of the egg-sharing
process and experience remain totally unexplored by researchers.
Much more needs to be known regarding the longer term expe-
riences of donors and recipients, their children and other family
members – and the experiences of donors and recipients who
ultimately remain childless – if the implications of egg sharing
are to be fully understood. The views and experiences of those
most personally affected by egg sharing remain silent voices in
current debates. This omission should not be perpetuated.
Five-year view
At present, information regarding the clinical and psycho–social
outcomes of egg sharing is extremely limited. We have identified
the key gaps in respect of clinical outcomes for both donors and
recipients and the absence of long-term evidence concerning the
experiences of women who have chosen to become egg-share
donors and of members of families that have been built using
egg sharing and, in particular, children who have been conceived
as a result of egg sharing. While we may expect to see some sim-
ilarities between the experiences of individuals personally
involved in egg sharing and those involved in other forms of
gamete donation, the particular characteristics of egg sharing
suggest that these experiences will not necessarily be equivalent
or comparable. For example, egg-share donors are clearly not in
the same position as egg donors who are not simultaneously
ART patients and (if critics of egg sharing are correct) children
conceived to recipients may have feelings regarding being
‘traded’ in exchange for their genetic mother’s treatment in addi-
tion to feelings regarding being separated deliberately from half
siblings who are likely to be of a similar age. We would both
hope and expect that, during the next 5 years, further clinical
and psycho–social research will be undertaken to ensure that
continuing debates regarding egg sharing are less dependent on
speculation and better informed by evidence.
Conclusion
While egg sharing globally appears to play a marginal role in the
maintenance of egg donation services and is not practiced at all
in many countries, it occupies a more prominent position in oth-
ers. In the UK, egg sharing has emerged as the principal source
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of donor eggs, yet remains subject to critical debate both in
terms of clinical and psycho–social outcomes and the extent to
which it accords with accepted ethical principles. To date, the
ethical debate has been confined to protagonists representing
exclusively professional interests; this needs to be extended to
ensure the active engagement of individuals who are most closely
involved in, and affected by, egg sharing at a personal level –
donors, recipients, their partners and their children. Only then
can we ensure that both debate and policy decisions are based on
the best quality and most relevant evidence that can be obtained.
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Key issues
• Egg sharing is practiced in a small number of countries globally.
• Egg sharing has become increasingly prevalent in the UK, where it is the major source of donor eggs.
• Advocates of egg sharing argue that it is a ‘win–win’ option, offering erstwhile unavailable services to both donors and recipients.
• The monetary value of a discounted treatment cycle in egg sharing is considerably higher than the upper limit of expenses payable to 
other gamete donors, leading to concerns that it represents the commodification of gamete procurement and may encourage a 
potential donor to disregard the risks of participation.
• More research is required to ensure that debates regarding egg sharing are better informed by knowledge of clinical and 
psycho–social outcomes.
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